Donald Notman

CIK: 0001718019

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)7 (70.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (30.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

OCUL

OCULAR THERAPEUTIX, INC

Officer

Discretionary Trading P&L

Holdings

Transaction History (10 total)

OCUL
OCULAR THERAPEUTIX, INC
Aug 31, 2026
Sale(S)
Direct
1.1K shares at avg. $10.24$11K
OCUL
OCULAR THERAPEUTIX, INC
Feb 12, 2026
Sale(S)
Direct
11.4K shares at avg. $9.04$103K
OCUL
OCULAR THERAPEUTIX, INC
Feb 4, 2026
Sale(S)
Direct
6K shares at avg. $8.54$52K
OCUL
OCULAR THERAPEUTIX, INC
Feb 2, 2026
Sale(S)
Direct
5.5K shares at avg. $9.14$50K
OCUL
OCULAR THERAPEUTIX, INC
Jan 2, 2026
Award(A)
Direct
79.1K shares-
OCUL
OCULAR THERAPEUTIX, INC
Sep 2, 2025
Sale(S)
Direct
1.1K shares at avg. $12.43$13K
OCUL
OCULAR THERAPEUTIX, INC
Feb 11, 2025
Award(A)
Direct
115K shares-
OCUL
OCULAR THERAPEUTIX, INC
Feb 4, 2025
Sale(S)
Direct
11.1K shares at avg. $7.81$87K
OCUL
OCULAR THERAPEUTIX, INC
Jan 31, 2025
Sale(S)
Direct
6.3K shares at avg. $7.84$49K
OCUL
OCULAR THERAPEUTIX, INC
Aug 29, 2024
Award(A)
Direct
11K shares-

		Type	Shares	Price		Ownership
Aug 31, 2026	OCUL OCULAR THERAPEUTIX, INC	Sale(S)	1,099	$10.24	$11,254	Direct
Feb 12, 2026	OCUL OCULAR THERAPEUTIX, INC	Sale(S)	11,446	$9.04	$103,472	Direct
Feb 4, 2026	OCUL OCULAR THERAPEUTIX, INC	Sale(S)	6,035	$8.54	$51,539	Direct
Feb 2, 2026	OCUL OCULAR THERAPEUTIX, INC	Sale(S)	5,455	$9.14	$49,859	Direct
Jan 2, 2026	OCUL OCULAR THERAPEUTIX, INC	Award(A)	79,112	-	$0	Direct
Sep 2, 2025	OCUL OCULAR THERAPEUTIX, INC	Sale(S)	1,066	$12.43	$13,250	Direct
Feb 11, 2025	OCUL OCULAR THERAPEUTIX, INC	Award(A)	115,000	-	-	Direct
Feb 4, 2025	OCUL OCULAR THERAPEUTIX, INC	Sale(S)	11,119	$7.81	$86,839	Direct
Jan 31, 2025	OCUL OCULAR THERAPEUTIX, INC	Sale(S)	6,301	$7.84	$49,400	Direct
Aug 29, 2024	OCUL OCULAR THERAPEUTIX, INC	Award(A)	11,034	-	$0	Direct

1-10 of 10 transactions

About Notman Donald

Notman Donald (SEC CIK 0001718019) files insider reports with the SEC as Chief Operating Officer of OCULAR THERAPEUTIX, INC (OCUL).

Signal8 holds 8 ownership filings by Notman Donald, all Form 4s, filed between Sep 3, 2024 and Sep 2, 2026. Those filings report 10 transactions, from Aug 29, 2024 to Aug 31, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Notman Donald's filings is in BEDFORD, MA.

Recent filings by Notman Donald

Aug 31, 2026: Open-market sale of OCUL shares (Form 4, code S).
Feb 12, 2026: Open-market sale of OCUL shares (Form 4, code S).
Feb 4, 2026: Open-market sale of OCUL shares (Form 4, code S).
Feb 2, 2026: Open-market sale of OCUL shares (Form 4, code S).
Jan 2, 2026: Grant or award of OCUL shares (Form 4, code A).

Other insiders filing for OCULAR THERAPEUTIX, INC (OCUL)

Anderman Todd, Chief Legal Officer
Kaiser Peter, Chief Development Officer
Heier Jeffrey S., Chief Scientific Officer
Nayak Sanjay, Chief Strategy Officer
Dugel Pravin
Warden Charles M, Director

How to read Form 4 transaction codes